NCT03995706
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must be planning to undergo craniotomy as part of standard of care
Exclusions: Patients who had prior treatment with sacituzumab govitecan
https://ClinicalTrials.gov/show/NCT03995706